Latest press releases

• 9Dec
  Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

   

• 25Nov
  Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)

   

• 19Nov
  Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome

   

• 29Oct
  Newron Initiates Outreach on First Global Rett Syndrome Burden of Illness Survey in Collaboration with the Rett Community

  

• 20Sep
  Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson’s disease in Japan

  

• 12Sep
  Newron reports half-year 2019 results